Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 3430.

https://doi.org/10.1182/blood.V128.22.3430.3430

Published: 2016

Journal Articles

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 5781.

https://doi.org/10.1182/blood.V128.22.5781.5781

Published: 2016

Journal Articles

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Fotios V. Michelis, MDPhD, Hans A. Messner, MD PhD, Jieun Uhm, MD, Naheed Alam, MBBS,MD, David Loach, MD, Laura McGillis, NP, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Dennis D. Kim, MD PhD

Blood (2014) 124 (21): 2529.

https://doi.org/10.1182/blood.V124.21.2529.2529

Published: 2014

Journal Articles

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Aamir Azeem, Rebecca M. Grunwald, Jieun Uhm, MD, Naheed Alam, MBBS, MD, Anna Lambie, NP, Laura McGillis, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1237.

https://doi.org/10.1182/blood.V124.21.1237.1237

Published: 2014

Journal Articles

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Rebecca M. Grunwald, Aamir Azeem, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Laura McGillis, NP, Anna Lambie, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1179.

https://doi.org/10.1182/blood.V124.21.1179.1179

Published: 2014

Journal Articles

The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes

Jieun Uhm, MD, Nada Hamad, MBBS Hons, FRACP, FRCPA, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Hans A. Messner, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD

Blood (2014) 124 (21): 3928.

https://doi.org/10.1182/blood.V124.21.3928.3928

Published: 2014

NARROW

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes

Email alerts

ASH Publications

American Society of Hematology

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only